Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.

@article{Bambeke2015DelafloxacinAN,
  title={Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.},
  author={Françoise Van Bambeke},
  journal={Future microbiology},
  year={2015},
  volume={10 7},
  pages={
          1111-23
        }
}
Delafloxacin is a fluoroquinolone lacking a basic substituent in position 7. It shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. It is currently… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019

Current Treatment Options for Acute Skin and Skin-structure Infections

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 63 REFERENCES

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.

  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2015

Delafloxacin exerts potent anti - gonococcal activity despite mutations that decrease antibiotic susceptibility due to target modification or drug efflux

SG Kurz, E Duffy, J Balthazar, RA Bomono, WM Shafer
  • 2014

Similar Papers

Loading similar papers…